English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background  Chronic myelomonocytic leukemia (CMML) is a hematological disease close to, but separate from both myeloproliferative disorders (MPD) and myelodysplastic syndromes and may show either myeloproliferative (MP-CMML) or myelodysplastic (MD-CMML) features. Not much is known about the molecular biology of this disease.    Methods  We studied a series of 30 CMML samples (13 MP- and 11 MD-CMMLs, and 6 acutely transformed cases) from 29 patients by using Agilent high density array-comparative genomic hybridization (aCGH) and sequencing of 12 candidate genes.    Results  Two-thirds of samples did not show any obvious alteration of aCGH profiles. In one-third we observed chromosome abnormalities (e.g. trisomy 8, del20q) and gain or loss of genes (e.g.  NF1 ,  RB1  and  CDK6 ).  RAS  mutations were detected in 4 cases (including an uncommon codon 146 mutation in  KRAS ) and  PTPN11  mutations in 3 cases. We detected 11  RUNX1  alterations (9 mutations and 2 rearrangements). The rearrangements were a new, cryptic inversion of chromosomal region 21q21-22 leading to break and fusion of  RUNX1  to  USP16 .  RAS  and  RUNX1  alterations were not mutually exclusive. RAS pathway mutations occurred in MP-CMMLs (~46%) but not in MD-CMMLs.  RUNX1  alterations (mutations and cryptic rearrangement) occurred in both MP and MD classes (~38%).    Conclusion  We detected RAS pathway mutations and RUNX1 alterations. The latter included a new cryptic  USP16-RUNX1  fusion. In some samples, two alterations coexisted already at this early chronic stage.

Genome profiling of chronic myelomonocytic leukemia: frequent alterations of RAS and RUNX1genes